# Oral Budesonide vs. Oral Mesalazine in Active Crohn's Disease (CD)

> **NCT00300118** · PHASE3 · COMPLETED · sponsor: **Dr. Falk Pharma GmbH** · enrollment: 311 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** budesonide
- **DRUG:** mesalazine

## Key facts

- **NCT ID:** NCT00300118
- **Lead sponsor:** Dr. Falk Pharma GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 311 (ACTUAL)
- **Last updated:** 2014-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00300118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00300118, "Oral Budesonide vs. Oral Mesalazine in Active Crohn's Disease (CD)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00300118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*